Involvement of the fibrogenic cytokines, TGF-β and bFGF, in the pathogenesis of idiopathic myelofibrosis

Pathologie Biologie

Volumn 49, Issue 2, 2001, Pages 153-157

  Le Bousse Kerdiles M C ^a   Martyre M C ^b  

^a HÔPITAL PAUL BROUSSE   (France)

^b INSTITUT CURIE   (France)

Author keywords

BFGF; Fibrogenic cytokines; Idiopathic myelofibrosis; TGF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CD34 ANTIGEN; CYTOKINE; TRANSFORMING GROWTH FACTOR BETA;

CONFERENCE PAPER; FIBROBLAST; MEGAKARYOCYTE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; POLYCLONAL ACTIVATION; PROTEIN EXPRESSION;

EID: 0035085317     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0369-8114(00)00021-3     Document Type: Conference Paper

References (61)

1. Some speculations on the myeloproliferative syndromes
2. The natural history of Agnogenic Myeloid Metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome
3. A G-6-PD variant with heterozygous expression in blood cells of a woman with primary myelofibrosis
4. Agnogenic myeloid metaplasia: A clonal proliferation of haematopoietic stem cells with secondary myelofibrosis
5. Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: Clonal analysis of a case characterized by a N-ras gene mutation
6. Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia
7. Multilineage expression of haemopoietic precursors with abnormal clone in idiopathic myelofibrosis
8. Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia
9. Pathogenesis of myelofibrosis: Role of ineffective megakaryopoiesis and megakaryocyte components
10. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-β in patients with myelofibrosis with myeloid metaplasia
11. The transforming growth factor-β family
12. The fibroblast growth factor family: Structural and biological properties
13. Idiopathic myelofibrosis. Clinical aspects and studies on extracellular matrix metabolism
14. Transforming growth factor-β and megakaryocytes in the pathogenesis of idiopathic myelofibrosis
15. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells
16. Long-term culture of human bone marrow stromal cells in the presence of basic fibroblast growth factor
17. "Pure" human hematopoietic progenitors: Permissive action of basic fibroblast growth factor
18. Basic fibroblast growth factor promotes the proliferation of human megakaryocyte progenitor cells
19. New insights into the regulation of megakaryocytopoiesis by haemopoietic and fibroblastic growth factors and transforming growth factor beta-1
20. Modulation of megakaryocytopoiesis by human basic fibroblast growth factor
21. Elevated levels of basic growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis
22. Release of basic fibroblast growth factor, and angiogenic factor devoid of secretory signal sequence: A trivial phenomenon or a novel secretion mechanism
23. Ultrastructure of the bone marrow tissue in so-called primary (idiopathic) myelofibrosisosteomyelosclerosis (agnogenic myeloid metaplasia). I. Abnormalities of megakaryopoiesis and thrombocytes
24. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system
25. Metabolism of receptor-bound and matrix-bound basic fibroblast growth factor by bovine capillary endothelial cells
26. Plasma VEGF levels in patients with primary myelofibrosis and other myeloproliferative disorders
27. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells whereas hypoxia upregulates VEGF expression only
28. Vascular endothelial growth factor in human glioma cell lines: Induced secretion by EGF, PDGF-BB, and bFGF
29. Effects of type β transforming growth factors on haematopoietic progenitor cells
30. Transforming growth factor β selectively inhibits normal and leukemic human bone marrow cell growth in vitro
31. The role of transforming growth factor-beta in hematopoiesis. A review
32. Basic fibroblast growth factor hematopoiesis
33. Autocrine transforming growth factor-β controls Go phase of early human hematopoietic progenitors in serum- or serum-free culture. Blood cell growth factors
34. Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor β1 or Rb oligonucleotides
35. Basic fibroblast growth factor counteracts the suppressive effect of transforming growth factor-β1 on human myeloid progenitor cells
36. Stem cell factor and basic fibroblast growth factor are synergistic in augmenting committed myeloid progenitor cell growth
37. Basic fibroblast growth factor (bFGF) induces early and late-stage hematopoietic progenitor cell colony formation (CFU-gm, CFU-meg, and BFUe) by synergizing with GM-CSF, Meg-CSF, and erythropoietin, and is a radioprotective agent in vitro
38. Basic fibroblast growth factor stimulates myelopoiesis in long-term human bone marrow cultures
39. Endogenous megakaryocyte colonies from peripheral blood in precursor cell
40. Increased granulocytic, erythrocytic and megakaryocytic progenitors in myelofibrosis with myeloid metaplasia
41. Blood and spleen haematopoiesis in patients with myelofibrosis
42. Circulating pluripotent haemopoietic cells in patients with myeloproliferative disorders
43. Characteristics of circulating megakaryocyte progenitors (CFU-MK) in patients with primary myelofibrosis
44. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders
45. Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3
46. Expression cloning of the TGF-β-type II receptor, a functional transmembrane serine/threonine kinase
47. Mechanism of activation of the TGF-β receptor
48. + hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia
49. + human hematopoietic progenitor cells through different cell kinetic mechanisms depending on the applied stimulus
50. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-β
51. Flg-2, a new member of the family of fibroblast growth factor receptors
52. Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors
53. Expression of fibroblast growth factor receptors in human leukemia cells
54. Peptide growth factors stimulate macrophage colony stimulating factor in murine stromal cells
55. Increased CSF-1 (M-CSF) in myeloproliferative disease: Association with myeloid metaplasia and peripheral bone marrow extension
56. CD44 and hyaluronan binding by human myeloid cells
57. Expression of basic fibroblast growth factor (bFGF) and FGF-receptors in human leukemic cells
58. Basic FGF treatment of endothelial cells down-regulates the 85-KDa TGFβ receptor subtype and decreases the growth inhibitory response to TGF-β1
59. Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia
60. Phenotypic diversity in human fibroblasts from myelometaplasic and non myelometaplasic hematopoietic tissues
61. Pathogenesis of idiopathic myelofibrosis: Present status and future directions